Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study

Introduction The approval of 9-δ-tetrahydocannabinol (THC)+cannabidiol (CBD) oromucosal spray (Sativex®) in Italy as an add-on medication for the management of moderate to severe spasticity in multiple sclerosis (MS) has provided a new opportunity for MS patients with drug-resistant spasticity. We a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurological sciences 2020-10, Vol.41 (10), p.2905-2913
Hauptverfasser:	Patti, Francesco, Chisari, Clara Grazia, Solaro, Claudio, Benedetti, Maria Donata, Berra, Eliana, Bianco, Assunta, Bruno Bossio, Roberto, Buttari, Fabio, Castelli, Letizia, Cavalla, Paola, Cerqua, Raffaella, Costantino, Gianfranco, Gasperini, Claudio, Guareschi, Angelica, Ippolito, Domenico, Lanzillo, Roberta, Maniscalco, Giorgia Teresa, Matta, Manuela, Paolicelli, Damiano, Petrucci, Loredana, Pontecorvo, Simona, Righini, Isabella, Russo, Margherita, Saccà, Francesco, Salamone, Giovanna, Signoriello, Elisabetta, Spinicci, Gabriella, Spitaleri, Daniele, Tavazzi, Eleonora, Trotta, Maria, Zaffaroni, Mauro, Zappia, Mario
Format:	Artikel
Sprache:	eng
Schlagworte:	Cannabidiol Cannabinoids Dronabinol Drug Combinations Drug development Drug resistance Humans Italy Medicine Medicine & Public Health Multiple sclerosis Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Muscle Spasticity - drug therapy Muscle Spasticity - etiology Neurology Neuroradiology Neurosciences Neurosurgery Original Article Patients Plant Extracts Psychiatry Retrospective Studies Spasticity Tetrahydrocannabinol THC
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!